Checked.be
Active
BE 0884.138.172Private limited company (pre-2019)
CHANS
Kapittelstraat 5 ·2610 Antwerpen, Belgium· 19 yrs active
Sector: Physiotherapy
(86951)
Conclusion
CHANS has been active since 2006 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €169k and a net result of €60. Equity is shrinking by ~8.5% per year across the filed fiscal years. Its solvency ranks better than 37% of 16012 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.1% (very low).
Based on the State Gazette, CBE and 4 annual accounts.
Key figures
| Equity | €169k |
| Net result | €60 |
| Better than sector | 37% |
| Active | 19 yrs |
Financial profile
52
/ 100
Mixed profile: strong on stability, weaker on profitability.
All 5 axes are computed from data Checked has read.
Health
61
Profitability
0
Solvency
66
Growth
32
Stability
100
Bankruptcy probability (12 mo)
Risk Assessment
0 / 100
Low riskTrust signals
Established
Founded in 2006, 19 years in business.
No legal incidents
No bankruptcy, reorganisation or interim measure in the Belgisch Staatsblad, and the KBO register records a normal legal situation.
Administrative Flags
No strikeouts found in the KBO publications we processed. That series starts in 2021 and has gaps, so this is not a confirmation that there is nothing.
Checked score
61
/ 100
Healthy
Computed from 5 of the 6 factors this model weighs. The rest cannot be derived from the filed figures, or need a prior year to compare against.
Indicative credit limit
€10k
estimate, not credit advice
Score history
81
2022
20
2023
62
2024
61
2025
purely financial, excl. current insolvency signals
Score components
Liquidity
Current ratio 0.67 (< 1.0)
-10
Leverage
Debt/equity 0.77 (< 1.0)
+10
Profitability
ROE 0%
+3
Interest coverage
Interest coverage 8.6× (≥ 3×)
+8
Profit trend
Net profit down YoY
-3
Equity growth
Equity growing YoY
+3
Computed by Checked from the NBB filing for FY 2025. Indicative, not credit advice.
Financial overview
Annual accounts filed on 26-02-2026 with the NBB · fiscal year 2025 · micro schema
Trajectory (indicative)
Projection over 3 fiscal years from the filed annual accounts, not a forecast, the extended trend.
declining
Equity: declining trend of ~8.5%/year over 4 fiscal years, indicative, assuming unchanged policy.
Solid line = filed figures · dashed = extended trend · area = indicative range.
How do we compute this?
The trend is a robust median of all pairwise slopes between fiscal years (Theil-Sen), so a single odd year cannot hijack the line. For strictly positive series we also fit a log variant (compound annual growth) and keep whichever describes the figures best.
The area around the projection is 1.8 × the median absolute deviation from the trend, widening each year ahead (×1 / ×1.6 / ×2.2), with a minimum of 8% of the last value. It is an indicative range, not a statistical confidence interval.
A series whose deviations exceed 35% of its level is too volatile: we then deliberately show no projection. Every projection assumes unchanged policy and is blind to non-public information (order book, contracts, funding rounds).
Sector comparison
Fiscal year 2025 · NACE 86, Human health activities · compared within the same schema type (micro schema)
| Metric | This company | Sector median | Position in the sector |
|---|---|---|---|
| Solvency | 47.7% | 63.4% | |
| Net result | €60 | €62k | |
| Equity | €169k | €132k | |
| Gross operating margin | €49k | €116k | |
| Total assets | €354k | €286k |
€42k
-27.6%
22-25
€60
-99.6%
22-25
€33k
-33.9%
22-25
€354k
-15.0%
22-25
€169k
0.0%
22-25
€-39k
-17.1%
22-25
3
-23.3%
22-25
€17k
-80.8%
22-25
€4k
+554.6%
22-25
€130k
-32.5%
22-25
€119k
-16.8%
22-25
€10k
-78.7%
22-25
0.67
-12.3%
22-25
0.67
-12.3%
22-25
47.7%
+17.7%
22-25
0.77
-32.5%
22-25
0.0%
-99.6%
22-25
0.0%
-99.6%
22-25
8.61
+9.5%
22-25
Figures by fiscal year and ratios
| Fiscal year | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Deposit | micro schema | micro schema | micro schema | micro schema |
| Revenue | - | - | - | - |
| EBITDA | €42k | €57k | €-10k | €152k |
| Net profit | €60 | €17k | €-56k | €44k |
| Cash flow | €33k | €50k | €-18k | €121k |
| Staff costs | - | - | €17k | €88k |
| Income taxes | €4k | €633 | €499 | €21k |
| Dividends | - | - | - | - |
| Total assets | €354k | €416k | €467k | €701k |
| Equity | €169k | €169k | €152k | €287k |
| Debt | €130k | €193k | €260k | €359k |
| of which ≤ 1y | €119k | €143k | €167k | €163k |
| of which > 1y | €10k | €48k | €93k | €194k |
| Working capital | €-39k | €-33k | €-40k | €38k |
| Employees (FTE) | - | - | 3.3 | 4.3 |
Ratios (computed)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Current ratio | 0.67 | 0.77 | 0.76 | 1.23 |
| Quick ratio | 0.67 | 0.77 | 0.76 | 1.23 |
| Working capital ratio | -11.0% | -8.0% | -8.5% | 5.4% |
| Solvency | 47.7% | 40.5% | 32.5% | 40.9% |
| Debt / equity | 0.77 | 1.14 | 1.71 | 1.25 |
| Long-term debt ratio | 0.06 | 0.29 | 0.62 | 0.68 |
| Interest coverage | 8.61 | 7.86 | -1.26 | 14.29 |
| Gross margin | - | - | - | - |
| Net margin | - | - | - | - |
| ROA | 0.0% | 4.0% | -12.0% | 6.3% |
| ROE | 0.0% | 10.0% | -36.9% | 15.4% |
| EBITDA margin | - | - | - | - |
| Days sales outstanding | - | - | - | - |
| Days payable outstanding | - | - | - | - |
| Inventory turnover | - | - | - | - |
| Days inventory (DSI) | - | - | - | - |
Balance-sheet composition 2025
Full annual accounts (25 line items)
Filed balance sheet and income statement, exactly as deposited with the NBB.
| Line item | Code | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Balance sheet, Assets | |||||
| TOTAL ASSETS | 20/58 | €354k | €416k | €467k | €701k |
| Fixed assets | 21/28 | €274k | €307k | €340k | €500k |
| Tangible fixed assets | 22/27 | €274k | €307k | €340k | €500k |
| Current assets | 29/58 | €80k | €109k | €127k | €201k |
| Amounts receivable within one year | 40/41 | €27k | €30k | €76k | €74k |
| Investments | 50/53 | €4k | €60k | €25k | €25k |
| Cash & bank | 54/58 | €49k | €20k | €26k | €102k |
| Balance sheet, Equity & liabilities | |||||
| TOTAL EQUITY & LIABILITIES | 10/49 | €354k | €416k | €467k | €701k |
| Equity | 10/15 | €169k | €169k | €152k | €287k |
| Contributions / capital | 10/11 | €13k | €13k | €13k | €19k |
| Reserves | 13 | €194k | €194k | €194k | €268k |
| Accumulated profits (losses) | 14 | €-39k | €-39k | €-56k | - |
| Provisions & deferred taxes | 16 | €55k | €55k | €55k | €55k |
| Amounts payable | 17/49 | €130k | €193k | €260k | €359k |
| Amounts payable after one year | 17 | €10k | €48k | €93k | €194k |
| Amounts payable within one year | 42/48 | €119k | €143k | €167k | €163k |
| Trade debts payable within one year | 44 | €6k | €7k | €3k | €14k |
| Income statement | |||||
| Gross operating margin | 9900 | €49k | €62k | €12k | €256k |
| Operating result | 9901 | €9k | €24k | €-48k | €75k |
| Financial income | 75 | €441 | €461 | €203 | €2k |
| Financial charges | 65 | €5k | €7k | €8k | €11k |
| Result before taxes | 9903 | €4k | €17k | €-56k | €66k |
| Income taxes | 67/77 | €4k | €633 | €499 | €21k |
| Net result for the period | 9904 | €60 | €17k | €-56k | €44k |
| Result to be appropriated | 9905 | €60 | €17k | €-56k | €44k |
Legal Structure
| NACE primary | Physiotherapy(86951) |
| Legal form | Private limited company (pre-2019)(015) |
| Incorporation | 10-10-2006 |
| Status | Active |
| Postal code | 2610 |
Establishment units
KINERENT
since 20062.157.224.372
Real-estate footprint
Flanders
1
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 11051B0362/00K006 | Flanders | 321 m² | 1 · 84 m² | 9.7 m · 3 fl. |
Methodology
via registered seat: 1
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Updates
Next filing, fiscal year 2026, expected by
2026
26-02
NBB filing
Annual accounts filed
fiscal year 2025 · micro schema · 26 days late
2025
28-02
NBB filing
Annual accounts filed
fiscal year 2024 · micro schema · 28 days late
2024
30-09
NBB filing
Annual accounts filed
fiscal year 2023 · micro schema · 243 days late
30-06
Financial
Back to profitnet €17k
Net result €17k after one loss-making year.
2023
30-06
Financial
Weakest financial yearnet €-56k ▼227%
Net result drops to €-56k, the lowest in the series; recovery starts the following year.
23-01
NBB filing
Annual accounts filed
fiscal year 2022 · micro schema
2022
28-02
NBB filing
Annual accounts filed
fiscal year 2021 · micro schema · 28 days late
10-01
NBB filing
Annual accounts filed
fiscal year 2020 · micro schema · 344 days late
2020
30-09
NBB filing
Annual accounts filed
fiscal year 2019 · micro schema · 243 days late
2019
19-02
NBB filing
Annual accounts filed
fiscal year 2018 · micro schema · 19 days late
2018
27-02
NBB filing
Annual accounts filed
fiscal year 2017 · abbreviated schema · 27 days late
2017
23-02
NBB filing
Annual accounts filed
fiscal year 2016 · abbreviated schema · 23 days late
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
Belgian State Gazette reading coverage
We know of 4 Belgian State Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
Credit advice
Company registry (CBE)
Activities
Physiotherapy86951Retail trade47740Retail sale of medical and orthopaedic goods, excluding prescription glasses and lenses4774152320Rental and leasing activities77225
Names & trade names
| Legal nameNL | CHANS |
Similar companies
Recover Janssens-Van Engelant
BE 0721.699.301 · Ninove
DVKinos
BE 0781.808.518 · Gerpinnes
CENTRE DE THERAPIE ROUSSEAU-FLAMENT
BE 0832.684.622 · Soignies
Kinepraktijk 't Lo
BE 0829.555.084 · Hamont-Achel
HA ELNEV
BE 0790.464.975 · Tienen